Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | AKT2 | P31751 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237031 | 0.97 | AKT1 (0.49) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| SCHEMBL14292182 | 0.97 | AKT1 (0.49) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| SCHEMBL1670244 | 0.94 | LOXL2 (0.51) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL29425077 | 0.92 | LOXL2 (0.50) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL22615435 | 0.92 | LOXL2 (0.50) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| SCHEMBL14292288 | 0.87 | LMNA (0.46) | LOXL2AKT1AKT2ALDH1A1TSHR | |
| SCHEMBL8283182 | 0.83 | HTR1A (0.50) | AKT1AKT2CYP4F2CYP4A11 | |
| SCHEMBL29010764 | 0.82 | LOXL2 (0.43) | LOXL2ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL17315678 | 0.81 | — | — | |
| SCHEMBL18662857 | 0.81 | AKT1 (0.50) | LOXL2AKT1AKT2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148971-A1 | DEUBIQUITINASE INHIBITORS | Pharmakea, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170088520-A1 | DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015187427-A1 | DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088520-A1 | DEUBIQUITINASE INHIBITORS | USP30, USP1, USP28 | LOXL2 1257/4885AKT1 2769/4885AKT2 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.